Related Experiment Video

Updated: Aug 24, 2025

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.5K

Evaluation of the Tocilizumab therapy in human cancers: Latest evidence and clinical potential

Kimia Ghasemi1, Kosar Ghasemi2

  • 1Department of Pharmacology and Toxicology, School of Pharmacy; Fertility and Infertility Research Center, Jundishapur University of Medical Sciences, Ahvaz, Iran.

Journal of Clinical Pharmacy and Therapeutics
|October 22, 2022
PubMed

Insights

Tocilizumab, an interleukin-6 receptor antagonist, effectively treats rheumatoid arthritis and COVID-19 by reducing inflammation. Researchers are exploring its potential in treating inflammation-associated cancers by targeting the IL-6/IL-6R axis.

Area of Science:

  • Immunology
  • Oncology
  • Pharmacology

Background:

  • Rheumatoid arthritis (RA) and COVID-19 involve significant inflammation.
  • Interleukin-6 (IL-6) and its receptor (IL-6R) play crucial roles in inflammatory processes.
  • Inflammatory mediators are implicated in the development of certain cancers.

Approach:

  • This review examines the role of the IL-6/IL-6R pathway in inflammation-associated cancers.
  • It discusses the therapeutic potential and challenges of using tocilizumab, an IL-6R antagonist, in cancer treatment.
  • Tocilizumab's efficacy in RA and COVID-19 provides a basis for exploring its anti-cancer applications.

Key Points:

  • Tocilizumab is an established treatment for rheumatoid arthritis and has shown promise in managing severe COVID-19.
  • The IL-6/IL-6R signaling pathway is a significant factor in tumorigenesis for inflammation-associated malignancies.
  • Targeting IL-6/IL-6R with tocilizumab presents a potential therapeutic strategy for specific cancer types.

Conclusions:

  • The IL-6/IL-6R axis is a critical target for managing inflammatory conditions and certain cancers.
  • Tocilizumab's anti-inflammatory properties suggest its utility in treating inflammation-driven cancers.
  • Further research is needed to fully establish the effectiveness and overcome challenges of using tocilizumab in oncology.
Keywords:
Actemracancerinterleukin 6interleukin 6 receptortocilizumab

More Related Videos

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells09:04

Analysis of Human T Cell Activity in an Allogeneic Co-Culture Setting of Pre-Treated Tumor Cells

Published on: March 7, 2025

616
Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors15:24

Testing Cancer Immunotherapeutics in a Humanized Mouse Model Bearing Human Tumors

Published on: December 16, 2022

3.2K

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
639
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
488
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
214